psalexa

In Vitro Diagnostic (IVD) Market Research Report: By Offering (Reagents & Kits, Instruments, Software & Services), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics, Hematology, Microbiology), Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases), End User (Hospitals & Clinics, Point of Care, Laboratories, Research & Academic Institutes) - Global Industry Analysis and Growth Forecast to 2030

  • Published: October 2020
  • Report Code: LS10210
  • Available Format: PDF
  • Pages: 344

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Offering

1.3.2 Market Segmentation by Technology

1.3.3 Market Segmentation by Application

1.3.4 Market Segmentation by End User

1.3.5 Market Segmentation by Region

1.3.6 Analysis Period

1.3.7 Market Data Reporting Unit

1.3.7.1 Value

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Offering

4.1.1.1 Reagents & kits

4.1.1.2 Instruments

4.1.1.3 Software & services

4.1.2 By Technology

4.1.2.1 Clinical chemistry

4.1.2.1.1 Basic metabolic panel

4.1.2.1.2 Lipid profile

4.1.2.1.3 Liver profile

4.1.2.1.4 Renal profile

4.1.2.1.5 Thyroid function panel

4.1.2.1.6 Others

4.1.2.2 Immunochemistry

4.1.2.2.1 ELISA

4.1.2.2.2 RIA

4.1.2.2.3 FIA

4.1.2.2.4 CLIA

4.1.2.2.5 ICA

4.1.2.2.6 Others

4.1.2.3 Molecular diagnostics

4.1.2.3.1 Infectious diseases

4.1.2.3.2 Genomics

4.1.2.3.3 Blood donor screening

4.1.2.3.4 Others

4.1.2.4 Hematology

4.1.2.4.1 CBC

4.1.2.4.2 Cholesterol testing

4.1.2.4.3 Blood glucose testing

4.1.2.4.4 Hemoglobin testing

4.1.2.4.5 Coagulation testing

4.1.2.4.6 Others

4.1.2.5 Others

4.1.3 By Application

4.1.3.1 Infectious diseases

4.1.3.2 Diabetes

4.1.3.3 Oncology

4.1.3.4 Cardiology

4.1.3.5 Nephrology

4.1.3.6 Autoimmune diseases

4.1.3.7 Others

4.1.4 By End User

4.1.4.1 Hospitals & clinics

4.1.4.2 POC

4.1.4.3 Research & academic institutes

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Approval and launch of new products

4.2.1.2 Increasing number of collaborations and agreements

4.2.2 Drivers

4.2.2.1 Regulations with respect to blood safety and sample contamination

4.2.2.2 Surging burden of chronic diseases

4.2.2.3 Increasing number of blood donors

4.2.2.4 Advancements in IVD technology

4.2.2.5 Increasing healthcare expenditure

4.2.2.6 Increasing number of hospitals and academic institutes

4.2.2.7 Impact analysis of drivers on the market forecast period

4.2.3 Restraints

4.2.3.1 Challenges in maintaining sufficient, safe sample supply

4.2.3.2 Data insecurity over donors’ demographic information

4.2.3.3 Cost-ineffectiveness of IVD products

4.2.3.4 Impact analysis of restraints on the market forecast

4.3 Porter’s Five Forces Analysis

4.4 Impact of COVID-19

Chapter 5. Global Market Size and Forecast

5.1 By Offering

5.2 By Technology

5.2.1 IVD Market for Clinical Chemistry, by Type

5.2.2 IVD Market for Immunochemistry, by Type

5.2.3 IVD Market for Molecular Diagnostics, by Type

5.2.4 IVD Market for Hematology, by Type

5.3 By Application

5.4 By End User

5.5 By Region

Chapter 6. North America Market Size and Forecast

6.1 By Offering

6.2 By Technology

6.2.1 IVD Market for Clinical Chemistry, by Type

6.2.2 IVD Market for Immunochemistry, by Type

6.2.3 IVD Market for Molecular Diagnostics, by Type

6.2.4 IVD Market for Hematology, by Type

6.3 By Application

6.4 By End User

6.5 By Country

6.5.1 U.S. Market Size and Forecast

6.5.1.1 By offering

6.5.1.2 By technology

6.5.1.2.1 IVD market for clinical chemistry, by type

6.5.1.2.2 IVD market for immunochemistry, by type

6.5.1.2.3 IVD market for molecular diagnostics, by type

6.5.1.2.4 IVD market for hematology, by type

6.5.1.3 By application

6.5.1.4 By end user

6.5.2 Canada Market Size and Forecast

6.5.2.1 By offering

6.5.2.2 By technology

6.5.2.2.1 IVD market for clinical chemistry, by type

6.5.2.2.2 IVD market for immunochemistry, by type

6.5.2.2.3 IVD market for molecular diagnostics, by type

6.5.2.2.4 IVD market for hematology, by type

6.5.2.3 By application

6.5.2.4 By end user

Chapter 7. Europe Market Size and Forecast

7.1 By Offering

7.2 By Technology

7.2.1 IVD Market for Clinical Chemistry, by Type

7.2.2 IVD Market for Immunochemistry, by Type

7.2.3 IVD Market for Molecular Diagnostics, by Type

7.2.4 IVD Market for Hematology, by Type

7.3 By Application

7.4 By End User

7.5 By Country

7.5.1 Germany Market Size and Forecast

7.5.1.1 By offering

7.5.1.2 By technology

7.5.1.2.1 IVD market for clinical chemistry, by type

7.5.1.2.2 IVD market for immunochemistry, by type

7.5.1.2.3 IVD market for molecular diagnostics, by type

7.5.1.2.4 IVD market for hematology, by type

7.5.1.3 By application

7.5.1.4 By end user

7.5.2 France Market Size and Forecast

7.5.2.1 By offering

7.5.2.2 By technology

7.5.2.2.1 IVD market for clinical chemistry, by type

7.5.2.2.2 IVD market for immunochemistry, by type

7.5.2.2.3 IVD market for molecular diagnostics, by type

7.5.2.2.4 IVD market for hematology, by type

7.5.2.3 By application

7.5.2.4 By end user

7.5.3 Italy Market Size and Forecast

7.5.3.1 By offering

7.5.3.2 By technology

7.5.3.2.1 IVD market for clinical chemistry, by type

7.5.3.2.2 IVD market for immunochemistry, by type

7.5.3.2.3 IVD market for molecular diagnostics, by type

7.5.3.2.4 IVD market for hematology, by type

7.5.3.3 By application

7.5.3.4 By end user

7.5.4 Spain Market Size and Forecast

7.5.4.1 By offering

7.5.4.2 By technology

7.5.4.2.1 IVD market for clinical chemistry, by type

7.5.4.2.2 IVD market for immunochemistry, by type

7.5.4.2.3 IVD market for molecular diagnostics, by type

7.5.4.2.4 IVD market for hematology, by type

7.5.4.3 By application

7.5.4.4 By end user

7.5.5 U.K. Market Size and Forecast

7.5.5.1 By offering

7.5.5.2 By technology

7.5.5.2.1 IVD market for clinical chemistry, by type

7.5.5.2.2 IVD market for immunochemistry, by type

7.5.5.2.3 IVD market for molecular diagnostics, by type

7.5.5.2.4 IVD market for hematology, by type

7.5.5.3 By application

7.5.5.4 By end user

Chapter 8. APAC Market Size and Forecast

8.1 By offering

8.2 By Technology

8.2.1 IVD Market for Clinical Chemistry, by Type

8.2.2 IVD Market for Immunochemistry, by Type

8.2.3 IVD Market for Molecular Diagnostics, by Type

8.2.4 IVD Market for Hematology, by Type

8.3 By Application

8.4 By End User

8.5 By Country

8.5.1 China Market Size and Forecast

8.5.1.1 By offering

8.5.1.2 By technology

8.5.1.2.1 IVD market for clinical chemistry, by type

8.5.1.2.2 IVD market for immunochemistry, by type

8.5.1.2.3 IVD market for molecular diagnostics, by type

8.5.1.2.4 IVD market for hematology, by type

8.5.1.3 By application

8.5.1.4 By end user

8.5.2 Japan Market Size and Forecast

8.5.2.1 By offering

8.5.2.2 By technology

8.5.2.2.1 IVD market for clinical chemistry, by type

8.5.2.2.2 IVD market for immunochemistry, by type

8.5.2.2.3 IVD market for molecular diagnostics, by type

8.5.2.2.4 IVD market for hematology, by type

8.5.2.3 By application

8.5.2.4 By end user

8.5.3 India Market Size and Forecast

8.5.3.1 By offering

8.5.3.2 By technology

8.5.3.2.1 IVD market for clinical chemistry, by type

8.5.3.2.2 IVD market for immunochemistry, by type

8.5.3.2.3 IVD market for molecular diagnostics, by type

8.5.3.2.4 IVD market for hematology, by type

8.5.3.3 By application

8.5.3.4 By end user

Chapter 9. LATAM Market Size and Forecast

9.1 By offering

9.2 By Technology

9.2.1 IVD Market for Clinical Chemistry, by Type

9.2.2 IVD Market for Immunochemistry, by Type

9.2.3 IVD Market for Molecular Diagnostics, by Type

9.2.4 IVD Market for Hematology, by Type

9.3 By Application

9.4 By End User

9.5 By Country

9.5.1 Brazil Market Size and Forecast

9.5.1.1 By offering

9.5.1.2 By technology

9.5.1.2.1 IVD market for clinical chemistry, by type

9.5.1.2.2 IVD market for immunochemistry, by type

9.5.1.2.3 IVD market for molecular diagnostics, by type

9.5.1.2.4 IVD market for hematology, by type

9.5.1.3 By application

9.5.1.4 By end user

9.5.2 Mexico Market Size and Forecast

9.5.2.1 By offering

9.5.2.2 By technology

9.5.2.2.1 IVD market for clinical chemistry, by type

9.5.2.2.2 IVD market for immunochemistry, by type

9.5.2.2.3 IVD market for molecular diagnostics, by type

9.5.2.2.4 IVD market for hematology, by type

9.5.2.3 By application

9.5.2.4 By end user

Chapter 10. MEA Market Size and Forecast

10.1 By offering

10.2 By Technology

10.2.1 IVD Market for Clinical Chemistry, by Type

10.2.2 IVD Market for Immunochemistry, by Type

10.2.3 IVD Market for Molecular Diagnostics, by Type

10.2.4 IVD Market for Hematology, by Type

10.3 By Application

10.4 By End User

10.5 By Country

10.5.1 Saudi Arabia Market Size and Forecast

10.5.1.1 By offering

10.5.1.2 By technology

10.5.1.2.1 IVD market for clinical chemistry, by type

10.5.1.2.2 IVD market for immunochemistry, by type

10.5.1.2.3 IVD market for molecular diagnostics, by type

10.5.1.2.4 IVD market for hematology, by type

10.5.1.3 By application

10.5.1.4 By end user

10.5.2 South Africa Market Size and Forecast

10.5.2.1 By offering

10.5.2.2 By technology

10.5.2.2.1 IVD market for clinical chemistry, by type

10.5.2.2.2 IVD market for immunochemistry, by type

10.5.2.2.3 IVD market for molecular diagnostics, by type

10.5.2.2.4 IVD market for hematology, by type

10.5.2.3 By application

10.5.2.4 By end user

Chapter 11. Competitive Landscape

11.1 Global IVD Market Share of Key Players

11.2 Strategic Developments of Key Players

11.2.1 Product Launches and Approvals

11.2.2 Mergers and Acquisitions

11.2.3 Other Developments

Chapter 12. Company Profiles

12.1 Thermo Fisher Scientific Inc.

12.1.1 Business Overview

12.1.2 Product and Service Offerings

12.1.3 Key Financial Summary

12.2 Danaher Corporation

12.2.1 Business Overview

12.2.2 Product and Service Offerings

12.2.3 Key Financial Summary

12.3 F. Hoffmann-La Roche Ltd.

12.3.1 Business Overview

12.3.2 Product and Service Offerings

12.3.3 Key Financial Summary

12.4 PerkinElmer Inc.

12.4.1 Business Overview

12.4.2 Product and Service Offerings

12.4.3 Key Financial Summary

12.5 Quidel Corporation

12.5.1 Business Overview

12.5.2 Product and Service Offerings

12.5.3 Key Financial Summary

12.6 OraSure Technologies Inc.

12.6.1 Business Overview

12.6.2 Product and Service Offerings

12.6.3 Key Financial Summary

12.7 Sysmex Corporation

12.7.1 Business Overview

12.7.2 Product and Service Offerings

12.7.3 Key Financial Summary

12.8 DIAGNOSTICA STAGO S.A.S

12.8.1 Business Overview

12.8.2 Product and Service Offerings

12.9 Siemens AG

12.9.1 Business Overview

12.9.2 Product and Service Offerings

12.9.3 Key Financial Summary

12.10 Abbott Laboratories

12.10.1 Business Overview

12.10.2 Product and Service Offerings

12.10.3 Key Financial Summary

12.11 Becton, Dickinson and Company

12.11.1 Business Overview

12.11.2 Product and Service Offerings

12.11.3 Key Financial Summary

12.12 Hologic Inc.

12.12.1 Business Overview

12.12.2 Product and Service Offerings

12.12.3 Key Financial Summary

12.13 Sartorius Stedim Biotech S.A.

12.13.1 Business Overview

12.13.2 Product and Service Offerings

12.13.3 Key Financial Summary

12.14 Bio-Rad Laboratories Inc.

12.14.1 Business Overview

12.14.2 Product and Service Offerings

12.14.3 Key Financial Summary

12.15 bioMérieux S.A.

12.15.1 Business Overview

12.15.2 Product and Service Offerings

12.15.3 Key Financial Summary

12.16 Trinity Biotech plc

12.16.1 Business Overview

12.16.2 Product and Service Offerings

12.16.3 Key Financial Summary

12.17 Bio-Techne Corporation

12.17.1 Business Overview

12.17.2 Product and Service Offerings

12.17.3 Key Financial Summary

12.18 DiaSorin S.p.A.

12.18.1 Business Overview

12.18.2 Product and Service Offerings

12.18.3 Key Financial Summary

12.19 Ortho-Clinical Diagnostics Inc.

12.19.1 Business Overview

12.19.2 Product and Service Offerings

12.20 Grifols S.A.

12.20.1 Business Overview

12.20.2 Product and Service Offerings

12.20.3 Key Financial Summary

Chapter 13. Appendix

13.1 Abbreviations

13.2 Sources and References

13.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 MARKET SIZE ANALYSIS PERIOD

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 5 GLOBAL IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 6 GLOBAL IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 7 GLOBAL IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 8 GLOBAL IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 9 GLOBAL IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 10 GLOBAL IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 11 GLOBAL IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 12 GLOBAL IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 13 GLOBAL IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 14 GLOBAL IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 15 GLOBAL IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 16 GLOBAL IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 17 GLOBAL IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 18 GLOBAL IVD MARKET, BY END USER, $M (2014–2019)

TABLE 19 GLOBAL IVD MARKET, BY END USER, $M (2020–2030)

TABLE 20 GLOBAL IVD MARKET, BY REGION, $M (2014–2019)

TABLE 21 GLOBAL IVD MARKET, BY REGION, $M (2020–2030)

TABLE 22 NORTH AMERICA IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 23 NORTH AMERICA IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 24 NORTH AMERICA IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 25 NORTH AMERICA IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 26 NORTH AMERICA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 27 NORTH AMERICA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 28 NORTH AMERICA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 29 NORTH AMERICA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 30 NORTH AMERICA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 31 NORTH AMERICA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 32 NORTH AMERICA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 33 NORTH AMERICA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 34 NORTH AMERICA IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 35 NORTH AMERICA IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 36 NORTH AMERICA IVD MARKET, BY END USER, $M (2014–2019)

TABLE 37 NORTH AMERICA IVD MARKET, BY END USER, $M (2020–2030)

TABLE 38 NORTH AMERICA IVD MARKET, BY COUNTRY, $M (2014–2019)

TABLE 39 NORTH AMERICA IVD MARKET, BY COUNTRY, $M (2020–2030)

TABLE 40 U.S. IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 41 U.S. IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 42 U.S. IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 43 U.S. IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 44 U.S. IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 45 U.S. IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 46 U.S. IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 47 U.S. IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 48 U.S. IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 49 U.S. IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 50 U.S. IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 51 U.S. IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 52 U.S. IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 53 U.S. IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 54 U.S. IVD MARKET, BY END USER, $M (2014–2019)

TABLE 55 U.S. IVD MARKET, BY END USER, $M (2020–2030)

TABLE 56 CANADA IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 57 CANADA IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 58 CANADA IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 59 CANADA IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 60 CANADA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 61 CANADA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 62 CANADA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 63 CANADA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 64 CANADA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 65 CANADA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 66 CANADA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 67 CANADA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 68 CANADA IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 69 CANADA IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 70 CANADA IVD MARKET, BY END USER, $M (2014–2019)

TABLE 71 CANADA IVD MARKET, BY END USER, $M (2020–2030)

TABLE 72 EUROPE IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 73 EUROPE IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 74 EUROPE IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 75 EUROPE IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 76 EUROPE IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 77 EUROPE IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 78 EUROPE IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 79 EUROPE IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 80 EUROPE IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 81 EUROPE IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 82 EUROPE IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 83 EUROPE IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 84 EUROPE IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 85 EUROPE IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 86 EUROPE IVD MARKET, BY END USER, $M (2014–2019)

TABLE 87 EUROPE IVD MARKET, BY END USER, $M (2020–2030)

TABLE 88 EUROPE IVD MARKET, BY COUNTRY, $M (2014–2019)

TABLE 89 EUROPE IVD MARKET, BY COUNTRY, $M (2020–2030)

TABLE 90 GERMANY IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 91 GERMANY IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 92 GERMANY IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 93 GERMANY IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 94 GERMANY IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 95 GERMANY IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 96 GERMANY IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 97 GERMANY IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 98 GERMANY IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 99 GERMANY IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 100 GERMANY IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 101 GERMANY IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 102 GERMANY IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 103 GERMANY IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 104 GERMANY IVD MARKET, BY END USER, $M (2014–2019)

TABLE 105 GERMANY IVD MARKET, BY END USER, $M (2020–2030)

TABLE 106 FRANCE IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 107 FRANCE IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 108 FRANCE IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 109 FRANCE IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 110 FRANCE IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 111 FRANCE IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 112 FRANCE IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 113 FRANCE IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 114 FRANCE IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 115 FRANCE IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 116 FRANCE IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 117 FRANCE IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 118 FRANCE IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 119 FRANCE IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 120 FRANCE IVD MARKET, BY END USER, $M (2014–2019)

TABLE 121 FRANCE IVD MARKET, BY END USER, $M (2020–2030)

TABLE 122 ITALY IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 123 ITALY IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 124 ITALY IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 125 ITALY IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 126 ITALY IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 127 ITALY IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 128 ITALY IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 129 ITALY IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 130 ITALY IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 131 ITALY IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 132 ITALY IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 133 ITALY IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 134 ITALY IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 135 ITALY IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 136 ITALY IVD MARKET, BY END USER, $M (2014–2019)

TABLE 137 ITALY IVD MARKET, BY END USER, $M (2020–2030)

TABLE 138 SPAIN IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 139 SPAIN IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 140 SPAIN IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 141 SPAIN IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 142 SPAIN IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 143 SPAIN IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 144 SPAIN IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 145 SPAIN IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 146 SPAIN IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 147 SPAIN IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 148 SPAIN IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 149 SPAIN IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 150 SPAIN IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 151 SPAIN IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 152 SPAIN IVD MARKET, BY END USER, $M (2014–2019)

TABLE 153 SPAIN IVD MARKET, BY END USER, $M (2020–2030)

TABLE 154 U.K. IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 155 U.K. IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 156 U.K. IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 157 U.K. IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 158 U.K. IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 159 U.K. IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 160 U.K. IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 161 U.K. IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 162 U.K. IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 163 U.K. IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 164 U.K. IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 165 U.K. IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 166 U.K. IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 167 U.K. IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 168 U.K. IVD MARKET, BY END USER, $M (2014–2019)

TABLE 169 U.K. IVD MARKET, BY END USER, $M (2020–2030)

TABLE 170 APAC IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 171 APAC IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 172 APAC IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 173 APAC IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 174 APAC IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 175 APAC IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 176 APAC IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 177 APAC IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 178 APAC IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 179 APAC IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 180 APAC IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 181 APAC IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 182 APAC IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 183 APAC IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 184 APAC IVD MARKET, BY END USER, $M (2014–2019)

TABLE 185 APAC IVD MARKET, BY END USER, $M (2020–2030)

TABLE 186 APAC IVD MARKET, BY COUNTRY, $M (2014–2019)

TABLE 187 APAC IVD MARKET, BY COUNTRY, $M (2020–2030)

TABLE 188 CHINA IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 189 CHINA IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 190 CHINA IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 191 CHINA IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 192 CHINA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 193 CHINA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 194 CHINA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 195 CHINA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 196 CHINA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 197 CHINA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 198 CHINA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 199 CHINA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 200 CHINA IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 201 CHINA IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 202 CHINA IVD MARKET, BY END USER, $M (2014–2019)

TABLE 203 CHINA IVD MARKET, BY END USER, $M (2020–2030)

TABLE 204 JAPAN IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 205 JAPAN IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 206 JAPAN IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 207 JAPAN IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 208 JAPAN IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 209 JAPAN IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 210 JAPAN IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 211 JAPAN IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 212 JAPAN IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 213 JAPAN IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 214 JAPAN IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 215 JAPAN IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 216 JAPAN IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 217 JAPAN IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 218 JAPAN IVD MARKET, BY END USER, $M (2014–2019)

TABLE 219 JAPAN IVD MARKET, BY END USER, $M (2020–2030)

TABLE 220 INDIA IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 221 INDIA IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 222 INDIA IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 223 INDIA IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 224 INDIA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 225 INDIA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 226 INDIA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 227 INDIA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 228 INDIA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 229 INDIA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 230 INDIA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 231 INDIA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 232 INDIA IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 233 INDIA IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 234 INDIA IVD MARKET, BY END USER, $M (2014–2019)

TABLE 235 INDIA IVD MARKET, BY END USER, $M (2020–2030)

TABLE 236 LATAM IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 237 LATAM IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 238 LATAM IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 239 LATAM IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 240 LATAM IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 241 LATAM IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 242 LATAM IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 243 LATAM IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 244 LATAM IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 245 LATAM IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 246 LATAM IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 247 LATAM IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 248 LATAM IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 249 LATAM IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 250 LATAM IVD MARKET, BY END USER, $M (2014–2019)

TABLE 251 LATAM IVD MARKET, BY END USER, $M (2020–2030)

TABLE 252 LATAM IVD MARKET, BY COUNTRY, $M (2014–2019)

TABLE 253 LATAM IVD MARKET, BY COUNTRY, $M (2020–2030)

TABLE 254 BRAZIL IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 255 BRAZIL IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 256 BRAZIL IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 257 BRAZIL IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 258 BRAZIL IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 259 BRAZIL IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 260 BRAZIL IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 261 BRAZIL IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 262 BRAZIL IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 263 BRAZIL IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 264 BRAZIL IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 265 BRAZIL IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 266 BRAZIL IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 267 BRAZIL IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 268 BRAZIL IVD MARKET, BY END USER, $M (2014–2019)

TABLE 269 BRAZIL IVD MARKET, BY END USER, $M (2020–2030)

TABLE 270 MEXICO IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 271 MEXICO IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 272 MEXICO IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 273 MEXICO IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 274 MEXICO IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 275 MEXICO IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 276 MEXICO IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 277 MEXICO IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 278 MEXICO IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 279 MEXICO IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 280 MEXICO IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 281 MEXICO IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 282 MEXICO IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 283 MEXICO IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 284 MEXICO IVD MARKET, BY END USER, $M (2014–2019)

TABLE 285 MEXICO IVD MARKET, BY END USER, $M (2020–2030)

TABLE 286 MEA IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 287 MEA IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 288 MEA IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 289 MEA IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 290 MEA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 291 MEA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 292 MEA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 293 MEA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 294 MEA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 295 MEA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 296 MEA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 297 MEA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 298 MEA IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 299 MEA IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 300 MEA IVD MARKET, BY END USER, $M (2014–2019)

TABLE 301 MEA IVD MARKET, BY END USER, $M (2020–2030)

TABLE 302 MEA IVD MARKET, BY COUNTRY, $M (2014–2019)

TABLE 303 MEA IVD MARKET, BY COUNTRY, $M (2020–2030)

TABLE 304 SAUDI ARABIA IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 305 SAUDI ARABIA IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 306 SAUDI ARABIA IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 307 SAUDI ARABIA IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 308 SAUDI ARABIA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 309 SAUDI ARABIA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 310 SAUDI ARABIA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 311 SAUDI ARABIA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 312 SAUDI ARABIA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 313 SAUDI ARABIA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 314 SAUDI ARABIA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 315 SAUDI ARABIA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 316 SAUDI ARABIA IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 317 SAUDI ARABIA IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 318 SAUDI ARABIA IVD MARKET, BY END USER, $M (2014–2019)

TABLE 319 SAUDI ARABIA IVD MARKET, BY END USER, $M (2020–2030)

TABLE 320 SOUTH AFRICA IVD MARKET, BY OFFERING, $M (2014–2019)

TABLE 321 SOUTH AFRICA IVD MARKET, BY OFFERING, $M (2020–2030)

TABLE 322 SOUTH AFRICA IVD MARKET, BY TECHNOLOGY, $M (2014–2019)

TABLE 323 SOUTH AFRICA IVD MARKET, BY TECHNOLOGY, $M (2020–2030)

TABLE 324 SOUTH AFRICA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 325 SOUTH AFRICA IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 326 SOUTH AFRICA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2014–2019)

TABLE 327 SOUTH AFRICA IVD MARKET FOR IMMUNOCHEMISTRY, BY TYPE, $M (2020–2030)

TABLE 328 SOUTH AFRICA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2014–2019)

TABLE 329 SOUTH AFRICA IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, $M (2020–2030)

TABLE 330 SOUTH AFRICA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2014–2019)

TABLE 331 SOUTH AFRICA IVD MARKET FOR HEMATOLOGY, BY TYPE, $M (2020–2030)

TABLE 332 SOUTH AFRICA IVD MARKET, BY APPLICATION, $M (2014–2019)

TABLE 333 SOUTH AFRICA IVD MARKET, BY APPLICATION, $M (2020–2030)

TABLE 334 SOUTH AFRICA IVD MARKET, BY END USER, $M (2014–2019)

TABLE 335 SOUTH AFRICA IVD MARKET, BY END USER, $M (2020–2030)

TABLE 336 THERMO FISHER SCIENTIFIC INC. – AT A GLANCE

TABLE 337 THERMO FISHER SCIENTIFIC INC. – KEY FINANCIAL SUMMARY

TABLE 338 DANAHER CORPORATION – AT A GLANCE

TABLE 339 DANAHER CORPORATION – KEY FINANCIAL SUMMARY

TABLE 340 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 341 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 342 PERKINELMER INC. – AT A GLANCE

TABLE 343 PERKINELMER INC. – KEY FINANCIAL SUMMARY

TABLE 344 QUIDEL CORPORATION – AT A GLANCE

TABLE 345 QUIDEL CORPORATION – KEY FINANCIAL SUMMARY

TABLE 346 ORASURE TECHNOLOGIES INC. – AT A GLANCE

TABLE 347 ORASURE TECHNOLOGIES INC. – KEY FINANCIAL SUMMARY

TABLE 348 SYSMEX CORPORATION – AT A GLANCE

TABLE 349 SYSMEX CORPORATION – KEY FINANCIAL SUMMARY

TABLE 350 DIAGNOSTICA STAGO S.A.S – AT A GLANCE

TABLE 351 SIEMENS AG – AT A GLANCE

TABLE 352 SIEMENS AG – KEY FINANCIAL SUMMARY

TABLE 353 ABBOTT LABORATORIES – AT A GLANCE

TABLE 354 ABBOTT LABORATORIES – KEY FINANCIAL SUMMARY

TABLE 355 BECTON, DICKINSON AND COMPANY – AT A GLANCE

TABLE 356 BECTON, DICKINSON AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 357 HOLOGIC INC. – AT A GLANCE

TABLE 358 HOLOGIC INC. – KEY FINANCIAL SUMMARY

TABLE 359 SARTORIUS STEDIM BIOTECH S.A. – AT A GLANCE

TABLE 360 SARTORIUS STEDIM BIOTECH S.A. – KEY FINANCIAL SUMMARY

TABLE 361 BIO-RAD LABORATORIES INC. – AT A GLANCE

TABLE 362 BIO-RAD LABORATORIES INC. – KEY FINANCIAL SUMMARY

TABLE 363 BIOMÉRIEUX S.A. – AT A GLANCE

TABLE 364 BIOMÉRIEUX S.A. – KEY FINANCIAL SUMMARY

TABLE 365 TRINITY BIOTECH PLC – AT A GLANCE

TABLE 366 TRINITY BIOTECH PLC. – KEY FINANCIAL SUMMARY

TABLE 367 BIO-TECHNE CORPORATION – AT A GLANCE

TABLE 368 BIO-TECHNE CORPORATION – KEY FINANCIAL SUMMARY

TABLE 369 DIASORIN S.P.A. – AT A GLANCE

TABLE 370 DIASORIN S.P.A. – PRODUCT AND SERVICE OFFERINGS

TABLE 371 DIASORIN S.P.A. – KEY FINANCIAL SUMMARY

TABLE 372 ORTHO-CLINICAL DIAGNOSTICS INC. – AT A GLANCE

TABLE 373 ORTHO-CLINICAL DIAGNOSTICS INC. – PRODUCT AND SERVICE OFFERINGS

TABLE 374 GRIFOLS S.A. – AT A GLANCE

TABLE 375 GRIFOLS S.A. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 6 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 7 DATA TRIANGULATION APPROACH

FIG 8 GLOBAL IVD MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 INTENSITY OF RIVALRY

FIG 12 THREAT OF NEW ENTRANTS

FIG 13 THREAT OF SUBSTITUTES

FIG 14 GLOBAL IVD MARKET SNAPSHOT (2019)

FIG 15 GLOBAL IVD MARKET, BY OFFERING, $M (2014–2030)

FIG 16 GLOBAL IVD MARKET, BY TECHNOLOGY, $M (2014–2030)

FIG 17 GLOBAL IVD MARKET, BY APPLICATION, $M (2014–2030)

FIG 18 GLOBAL IVD MARKET, BY END USER, $M (2014–2030)

FIG 19 GLOBAL IVD MARKET, BY REGION, $M (2014–2030)

FIG 20 NORTH AMERICA IVD MARKET SNAPSHOT

FIG 21 NORTH AMERICA IVD MARKET, BY OFFERING, $M (2014–2030)

FIG 22 NORTH AMERICA IVD MARKET, BY TECHNOLOGY, $M (2014–2030)

FIG 23 NORTH AMERICA IVD MARKET, BY APPLICATION, $M (2014–2030)

FIG 24 NORTH AMERICA IVD MARKET, BY END USER, $M (2014–2030)

FIG 25 NORTH AMERICA IVD MARKET, BY COUNTRY, $M (2014–2030)

FIG 26 EUROPE IVD MARKET SNAPSHOT

FIG 27 EUROPE IVD MARKET, BY OFFERING, $M (2014–2030)

FIG 28 EUROPE IVD MARKET, BY TECHNOLOGY, $M (2014–2030)

FIG 29 EUROPE IVD MARKET, BY APPLICATION, $M (2014–2030)

FIG 30 EUROPE IVD MARKET, BY END USER, $M (2014–2030)

FIG 31 EUROPE IVD MARKET, BY COUNTRY, $M (2014–2030)

FIG 32 APAC IVD MARKET SNAPSHOT

FIG 33 APAC IVD MARKET, BY OFFERING, $M (2014–2030)

FIG 34 APAC IVD MARKET, BY TECHNOLOGY, $M (2014–2030)

FIG 35 APAC IVD MARKET, BY APPLICATION, $M (2014–2030)

FIG 36 APAC IVD MARKET, BY END USER, $M (2014–2030)

FIG 37 APAC IVD MARKET, BY COUNTRY, $M (2014–2030)

FIG 38 LATAM IVD MARKET SNAPSHOT

FIG 39 LATAM IVD MARKET, BY OFFERING, $M (2014–2030)

FIG 40 LATAM IVD MARKET, BY TECHNOLOGY, $M (2014–2030)

FIG 41 LATAM IVD MARKET, BY APPLICATION, $M (2014–2030)

FIG 42 LATAM IVD MARKET, BY END USER, $M (2014–2030)

FIG 43 LATAM IVD MARKET, BY COUNTRY, $M (2014–2030)

FIG 44 MEA IVD MARKET SNAPSHOT

FIG 45 MEA IVD MARKET, BY OFFERING, $M (2014–2030)

FIG 46 MEA IVD MARKET, BY TECHNOLOGY, $M (2014–2030)

FIG 47 MEA IVD MARKET, BY APPLICATION, $M (2014–2030)

FIG 48 MEA IVD MARKET, BY END USER, $M (2014–2030)

FIG 49 MEA IVD MARKET, BY COUNTRY, $M (2014–2030)

FIG 50 GLOBAL IVD MARKET SHARE OF KEY PLAYERS, 2019

FIG 51 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 52 DANAHER CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 53 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2019)

FIG 54 PERKINELMER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 55 QUIDEL CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 56 ORASURE TECHNOLOGIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 57 SYSMEX CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 58 SIEMENS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 59 ABBOTT LABORATORIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 60 BECTON, DICKINSON AND COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 61 HOLOGIC INC. – REVENUE SPLIT BY PRODUCT SEGMENT AND GEOGRAPHY (2019)

FIG 62 SARTORIUS STEDIM BIOTECH S.A. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 63 BIO-RAD LABORATORIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 64 BIOMÉRIEUX S.A. – REVENUE SPLIT BY APPLICATION AND GEOGRAPHY (2018)

FIG 65 TRINITY BIOTECH PLC. – REVENUE SPLIT BY SEGMENT (2018)

FIG 66 BIO-TECHNE CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 67 DIASORIN S.P.A. – REVENUE SPLIT BY TECHNOLOGY AND GEOGRAPHY (2018)

FIG 68 GRIFOLS S.A. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

Place An Order
USD 4900 USD 6400 USD 8400
Customized Report Solution

Get a bespoke market intelligence solution

 
We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need Us

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws